Kenneth Bramlett, MD
Sports Medicine · Vestavia Hills, ALNPI 1164449518
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Prime Surgical, LLC at 27.4% of the total. Reporting peaked in 2019 at $3,212 and has fallen 75.1% since, to $799 in 2025.
Across 109 payments — averaging $62.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Prime Surgical, LLC$2K
- Zimmer Biomet$1K
- Smith+Nephew$967
- Johnson & Johnson$637
- Pacira Therapeutics, Inc.$428
- Hikma Pharmaceuticals USA$423
- plus $1K from 18 others
What the payments were for
- Consulting fees$4236%
- Travel & lodging$77211%
- Food & beverage$3,71355%
- Education$1,85527%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Prime Surgical, LLC | 1 | $1,855 |
| Zimmer Biomet | 18 | $1,335 |
| Smith+Nephew | 18 | $967 |
| Johnson & Johnson(2 entities) | 17 | $637 |
| Pacira Therapeutics, Inc. | 16 | $428 |
| Hikma Pharmaceuticals USA | 1 | $423 |
| Amgen(2 entities) | 6 | $238 |
| Conformis, Inc. | 2 | $197 |
| Stryker | 2 | $142 |
| Baudax Bio Inc. | 5 | $89 |
| Abbott | 3 | $64 |
| Boston Scientific | 4 | $62 |
| Convatec Inc. | 3 | $61 |
| Heron Therapeutics, Inc. | 2 | $47 |
| Bioventus LLC | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 1 | $34 |
| Acumed LLC | 1 | $29 |
| Pfizer | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Si-bone, Inc. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| ERMI LLC | 1 | $13 |
| Heraeus Medical, LLC. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ROSA$424
- COMBOGESIC IV$423
- Persona$359
- CORI$209
- Journey Uni$209
- ARIA$209
- T-Fix$170
- Journey II BCS$170
- PICO 7 Single Use Negative Pressure Wound Therapy$170
- REDAPT Revision Hip System$170
- MAKO$131
- VISTASEAL$124
- STRATAFIX$124
- DERMABOND PRINEO$124
- KRYSTEXXA$122
- RELIGN$115
- Sports Medicine-None$103
- iTotal CR$102
- NAVIO$101
How this compares
$6,763 in reported general payments places this provider in the 60th percentile of 108 sports medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Etodolac | 154 | $6,549 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 370 | $4,245 |
| EliquisApixaban | 15 | $3,986 |
| Methocarbamol | 379 | $1,860 |
| Celecoxib | 50 | $1,655 |
| Doxycycline Hyclate | 86 | $1,339 |
| Meloxicam | 260 | $989 |
| Methylprednisolone | 64 | $590 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $421 |
| Diclofenac Sodium | 22 | $266 |
| Amoxicillin | 80 | $217 |
| Tramadol Hcl | 67 | $210 |
| Cephalexin | 24 | $147 |
| Cyclobenzaprine Hcl | 15 | $140 |
| Ondansetron OdtOndansetron | 14 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $3,98615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 108 sports medicine providers in Alabama.
Other sports medicine in Vestavia Hills
- Edward CainBirmingham$12.7M
- Daniel MatthewsDaphne$190K
- Mark RogersBirmingham$94K
- Amit MomayaBirmingham$77K
- Matthew SmithGuntersville$73K
- Christoper GarrettBirmingham$58K
- Jonathan IsbellHoover$55K
- James McMurtrieHuntsville$54K
- Reaves CrabtreeBirmingham$47K
- David AdkisonBirmingham$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.